Related Experiment Video

Updated: Jun 16, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis

V Cepero1, J R Sierra, S Giordano

  • 1Institute for Cancer Research and Treatment, University of Torino Medical School, S.P.142 Km 3.9, 10060 Candiolo (TO), Italy.

Current Pharmaceutical Design
|February 20, 2010
PubMed

Insights

New cancer treatments target specific molecules driving cancer growth. This review focuses on inhibitors targeting tyrosine kinases, crucial for cancer cell survival and signaling pathways.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cancer development knowledge has advanced, leading to molecular targeted therapies.
  • Targeted drugs inhibit specific molecules crucial for maintaining cancer's malignant state.
  • Activated oncogenes are key drivers, with tyrosine kinases playing a critical role in many human cancers.

Purpose of the Study:

  • To review strategies for inhibiting tyrosine kinases and their associated signal transduction pathways in cancer therapy.
  • To highlight the role of "oncogene addiction" in making protein kinases ideal therapeutic targets.

Main Methods:

  • Focuses on reviewing existing literature and strategies.
  • Concentrates on inhibitors, primarily monoclonal antibodies and small-molecules.
  • Examines tyrosine kinases and their signal transduction pathways as therapeutic targets.

Main Results:

  • Tyrosine kinases are critical oncogenes in human cancers.
  • Cancer cells often depend on continuous oncogene expression for survival ("oncogene addiction").
  • Inhibitors targeting these kinases represent a promising therapeutic approach.

Conclusions:

  • Targeted inhibition of tyrosine kinases and their pathways is a rapidly growing area in cancer therapy.
  • Understanding oncogene addiction supports the development of kinase-targeted drugs.
  • This review provides a focused overview of tyrosine kinase inhibition strategies.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...